Offshore Drillers: Cutting Their Way to Big Beats
The first offshore drillers–Noble (NE) and Ensco (ESV) have started reporting their third-quarter financial results–and while their numbers have been boosted by cost cutting, investors don’t seem to...
View ArticleNewmont & Barrick: There’s Gold in Them There Shares
Shares of Barrick Gold (ABX) and Newmont Mining (NEM) are shining today after reporting better-than-forecast earnings today. Bloomberg News Morgan Stanley’s Brad Humphrey and Thomas Halton explain why...
View ArticleBuffalo Wild Wings: The Opposite of Flight
Whenever a stock has plunged the way Buffalo Wild Wings (BWLD) has today, you know an analyst will cut his or her rating despite knowing that ridicule will soon follow. Wells Fargo’s Jeff Farmer and...
View ArticleWill Vertex Finally Turn a Profit?
UBS analyst Matthew Roden and team argue that profitability for Vertex Pharmaceuticals (VRTX) is “just around the corner.” They explain why: Gregory Bull/Associated Press Vertex reported a strong 3Q,...
View ArticleWhy Allergan Should Buy Pfizer (Yes, You Read That Right)
Last night, reports emerged that suggested Pfizer (PFE) was in talks to purchase Allergan (AGN). Credit Suisse analyst Vamil Divan and team think they have it backwards: Bloomberg News Our assessment...
View ArticleDelphi & Borg Warner: To the Junkyard With You!
Shares of auto-part makers Borg Warner (BWA) and Delphi Automotive (DLPH) are getting hammered today after beating earnings forecasts but lowering guidance. Volvo Car Group Wells Fargo’s Richard Kwas...
View ArticleGNC: ‘The Outlook Isn’t Promising’ and That Might Be an Understatement
Sterne Agae CRT’s Charles Grom and team can’t hide their disappointment in GNC Holdings (GNC) following today’s disastrous earnings: Rick Wilking/Reuters Today’s 3Q15 print from GNC didn’t bolster...
View ArticleValeant: A Defense, a Rumor, a Tumble
Sequoia’s Robert Goldfarb and David Poppe defended Valeant Pharmaceuticals International (VRX)–and their massive stake in it–even as two board members quit in protest. From their letter: Reuters...
View ArticleMorning Movers: Exxon, AbbVie Jump on Earnings; Valeant Slumps
Stocks look set to tick higher this morning after Congress passed a budget that would prevent a U.S. debt default. David Carson/Associated Press S&P 500 futures have ticked up 0.1%, while Dow Jones...
View ArticleTesla Motors: More Questions Than Answers
UBS analyst Colin Langan and Eddie Hsieh argue that there are “more questions than answers” when it comes to Tesla Motors (TSLA): Associated Press Can Tesla hit FY delivery targets? Over the last few...
View ArticleWhy AbbVie is Soaring
Credit Suisse analyst Vamil Divan and team explain why AbbVie’s (ABBV) earnings and guidance have been “very well received”: Associated Press AbbVie’s 3Q EPS beat Credit Suisse/Consensus expectations...
View ArticleGenworth Financial: Surprise, Surprise, Another Disappointment
Genworth Financial (GNW) reported another set of disappointing numbers but JPMorgan’s Jimmy Bhullar and team contend that the results aren’t as bad as “they appear at first glance.” They explain why:...
View ArticleBoston Beer Loses Its Fizz
Shares of Boston Beer (SAM) have tumbled today after the maker of Sam Adams beat earnings but lowered its full-year guidance last night. Cowen’s Vivien Azer and Gerald Pascarelli blame “intense...
View ArticleGilead Sciences: Its Hepatitis-C Treatments Keep Getting Better
Gilead Sciences (GILD) was first to market with its hepatitis-C treatments, and if the FDA’s concerns around AbbVie’s (ABBV) drugs is any indication, they’re safer too. And it looks like they will keep...
View ArticleExxonMobil Rises on Earnings Beat
Wells Fargo’s Roger Read likes what he sees from ExxonMobil’s (XOM) earnings: Bloomberg News Exxon delivered a headline EPS beat with Q3 2015 results of $1.01 versus our estimate of $0.92 and consensus...
View ArticleValeant: Is There Anything Else?
Mizuho’s Irina Koffler discusses wonders if Valeant Pharmaceuticals International (VRX) will have to disclose anything else after ending its relationship with Philidor: Lucas Jackson/Reuters Valeant is...
View ArticleChevron: It’s Not ExxonMobil But No One Seems to Mind
S&P Capital IQ’s Stewart Glickman looks at earnings from Chevron (CVX) and ExxonMobil (XOM), and notes that Chevron continues to underperform its larger peer: Photo: Stephen Morton/Bloomberg News...
View ArticleCVS: Buy Shares on Weakness?
Leerink’s David Larsen and Chris Abbott think investors should be buying shares of CVS Health (CVS) on weakness following its disappointing guidance. They explain why: Getty Images On the call,...
View Article20 Stocks For Higher Rates
Fundstrat’s Thomas Lee and team note that the U.S. dollar usually weakens following the first rate hike, making companies like Qualcomm (QCOM), General Electric (GE), Fossil (FOSL), Dow Chemical (DOW),...
View ArticleStocks Slip, But Have Their Best Month In Four Years
Investors were spooked Friday, sending major indexes lower, but stock are easily in the black for October. Agence France-Presse/Getty Images The Dow Jones Industrial Average gained 1378.84 points, or...
View Article
